Publications by authors named "Gregory Winchell"

Claim this Profile
P
Pharmacokinetics and safety of single and repeat doses of ceftibuten in healthy participants: a phase 1 dose escalation study.
Mary Beth Dorr, Carlos Fernando de Oliveira, Jeroen van de Wetering, Kathryn Lowe, Philip Sabato, Gregory Winchell

Antimicrob Agents Chemother· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetics of single and multiple doses of ledaborbactam etzadroxil with or without ceftibuten in healthy volunteers.
Carlos Fernando de Oliveira, Mary Beth Dorr, Jeroen van de Wetering, Kathryn Lowe, Philip Sabato, Gregory Winchell

Antimicrob Agents Chemother· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A population pharmacokinetic model for posaconazole intravenous solution and oral powder for suspension formulations in pediatric patients with neutropenia.
Gregory Winchell, Rik de Greef, Aziz Ouerdani, Floris Fauchet, Rebecca E Wrishko

Antimicrob Agents Chemother· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and Exposure Response Analysis of the Double-Blind Randomized Study of Posaconazole and Voriconazole for Treatment of Invasive Aspergillosis.
Johan A Maertens, Galia Rahav, Dong-Gun Lee, Shariq Haider, Isabel Cristina Ramirez-Sanchez, Gregory A Winchell

Clin Drug Investig· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III).
Thomas J Sferra, Tomas Merta, Michael Neely, Claudia Murta de Oliveira, Alvaro Lassaletta, Gregory Winchell

J Pediatric Infect Dis Soc· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-Informed Dose Justifications of Posaconazole in Japanese Patients for Prophylaxis and Treatment Against Fungal Infection.
Takashi Iwasa, Camila de Almeida, Floris Fauchet, Gregory A Winchell, Rik de Greef

J Clin Pharmacol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b/3 Pharmacokinetics and Safety Study of Intravenous Posaconazole in Adult Asian Participants at High Risk for Invasive Fungal Infections.
Depei Wu, Yingchang Mi, Jianyu Weng, Junling Zhuang, Xiaoyan Ke, Gregory A Winchell

Adv Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial.
Andreas H Groll, Hisham Abdel-Azim, Thomas Lehrnbecher, William J Steinbach, Amanda Paschke, Gregory A Winchell

Int J Antimicrob Agents· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection.
Kaiyan Liu, Depei Wu, Junmin Li, Hu Chen, Hongmei Ning, Gregory A Winchell

Adv Ther· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Caspofungin exposure-response relationships in adult patients with mucosal or invasive candidiasis.
Wendy Comisar, Peng Sun, Susan Li, Carole Sable, Michael Schwartz, Gregory Winchell

Clin Pharmacol Drug Dev· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants.
Elizabeth M Migoya, Goutam C Mistry, Julie A Stone, Wendy Comisar, Peng Sun, Gregory A Winchell

J Clin Pharmacol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-based decision making in early clinical development: minimizing the impact of a blood pressure adverse event.
Mark Stroh, Carol Addy, Yunhui Wu, S Aubrey Stoch, Nazaneen Pourkavoos, Gregory A Winchell

AAPS J· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations.
Goutam C Mistry, Elizabeth Migoya, Paul J Deutsch, Gregory Winchell, Michael Hesney

J Clin Pharmacol· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Arthur J Bergman, Catherine Stevens, YanYan Zhou, Bingming Yi, Martine Laethem, Gregory Winchell

Clin Ther· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
Gary A Herman, Cathy Stevens, Kristien Van Dyck, Arthur Bergman, Bingming Yi, Gregory Winchell

Clin Pharmacol Ther· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of ketoconazole on the pharmacokinetics of a selective alpha 1A-adrenoceptor antagonist.
Gregory A Winchell, Goutam C Mistry, Prasad P Kari, Thomas Marbury, Jutta L Miller

J Clin Pharmacol· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients.
Frank S Rhame, Sandy L Rawlins, Richard A Petruschke, Tara A Erb, Gregory A Winchell

Antimicrob Agents Chemother· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential for interactions between caspofungin and nelfinavir or rifampin.
Julie A Stone, Elizabeth M Migoya, Lisa Hickey, Gregory A Winchell, Paul J Deutsch

Antimicrob Agents Chemother· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indinavir and rifabutin drug interactions in healthy volunteers.
Walter K Kraft, Jacqueline B McCrea, Gregory A Winchell, Alexandra Carides, Richard Lowry

J Clin Pharmacol· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma.
Julie A Stone, Xin Xu, Gregory A Winchell, Paul J Deutsch, Paul G Pearson

Antimicrob Agents Chemother· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.
Julie A Stone, Sherry D Holland, Peter J Wickersham, Andrew Sterrett, Michael Schwartz, Gregory A Winchell

Antimicrob Agents Chemother· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclobenzaprine pharmacokinetics, including the effects of age, gender, and hepatic insufficiency.
Gregory A Winchell, Joyce D King, Cynthia M Chavez-Eng, Marvin L Constanzer, Scott H Korn

J Clin Pharmacol· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis